. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: J Mammary Gland Biol Neoplasia. 2012 Jul 27;17(3-4):191–204. doi: 10.1007/s10911-012-9263-3

Table 1.

Epigenetic modifiers in clinical investigation

Class	Agent	Alternative name	FDA Approved
HDAC inhibitors
Hydroxamic Acid	Vorinostat	SAHA, suberoylanilide hydroxamic acid	CTCL
	Panobinostat	LBH-589	–
	Belinostat	PXD-101	–
	CHR-3996	–	–
	Tefinostat	CHR-2845	–
	JNJ-26481585	–	–
Benzamide	Entinostat	MS-275	–
	CI-994	Tacedinaline, acetyldinaline	–
	MGCD-0103	Mocetinostat	–
Cyclic Peptide	Romidepsin	Depsipeptide (FK-228)	CTCL
Small Chain Fatty Acid	Valproic acid	–	Seizures, mania, migraine prophylaxis
Small Chain Fatty Acid	Phenylbutyrate	–	Urea cycle disorders
DNMT inhibitors
Nucleoside analogues	Azacitidine	5-AZA, 5-AC, 5-azacytidine, azacytidine, ladakamycin	MDS
	Decitabine	5-aza-dCyd, deoxyazacytidine, 2-deoxy-5- azacytidine, dezocitidine	MDS
	SGI-110	–	–

HDAC histone deacetylase, DNMT DNA methyltransferase, CTCL cutaneous T cell lymphoma, MDS myelodysplasia